HPV Genotyping via E6/E7 Region Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current high-risk human papillomavirus (HR-HPV) screening methods often fail to accurately genotype individual HPV types, leading to potential delays in monitoring and treatment due to false negative results, especially when targeting the L1 region, which is prone to integration events resulting in partial or complete loss of the open reading frame.
Innovation Solution
The development of nucleic acid primers and probes specifically designed for the E6/E7 region of HPV 16, 18, and 45 genomes, ensuring 70-100% identity and specificity to detect and differentiate between these types without cross-reactivity, allowing for accurate genotyping and quantification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If L1 region-based PCR assays are used for HR-HPV screening, then screening coverage is achieved, but false negative results occur due to integration events causing loss of the open reading frame
Solution Approach 1:
The patent extracts the detection target from the L1 region to the E6/E7 region of the HPV genome. By designing primers and probes that specifically target the E6/E7 region instead of L1, the method avoids integration events that cause loss of the L1 open reading frame, thereby eliminating false negatives while maintaining screening coverage
Solution Approach 2:
The patent applies local quality by designing type-specific primers and probes with 70-100% identity to the E6/E7 region of specific HPV types (16, 18, 45). This localized optimization of primer/probe sequences for each HPV type enables accurate genotyping without cross-reactivity, resolving the contradiction between broad screening and precise type identification
2Productivity
If consensus primers are used to detect entire group of HR-HPV, then screening efficiency is improved, but individual HPV type genotyping capability is lost
Solution Approach 1:
The patent segments the detection approach by using a panel of type-specific primers and probes for different HPV types (16, 18, 45) rather than a single consensus primer. Each primer/probe set is optimized for its specific target type, allowing simultaneous detection and precise genotyping of multiple HPV types in a single assay, thus maintaining both efficiency and precision
Solution Approach 2:
The patent creates a multi-functional assay system where the same PCR platform and detection methodology can identify multiple HPV types (16, 18, 45) simultaneously. The universal assay structure maintains screening efficiency while the type-specific primers and probes enable precise genotyping, achieving both goals through multi-functionality
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables precise detection and quantification of HR-HPV types, reducing false negatives and improving the accuracy of HR-HPV screening by targeting a region less prone to mutagenic events during integration, thereby enhancing the monitoring and treatment of high-risk HPV infections.
Implementation Method 1
hybridizing at least one nucleic acid primer or probe according to claim 1 to at least a portion of a target sequence in an E6/E7 region of a first high-risk HPV genome
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Nucleic acids, assays, and methods for the detection and quantification of high risk HPV types are disclosed.